← Leaderboards
Napoleone Ferrara
University Of California, San Diego
$2,482,045
Attributed
$2,697,967
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $481.9K · FY2018–24$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,697,967 · 2
By mechanism
R01$2,266,123 · 1
R21$431,844 · 1
Top collaborators
- William Fenical2 shared
Most similar at University Of California, San Diego
Same institution · by research overlap
- Bradley S Moore$17,879,881
- Lena Gerwick$2,120,964
- Zhen Bouman Chen$6,346,889
- Ramunas Stepanauskas$789,434
- Tanja Woyke$588,732
Others in their field
Other Emerging Leaders on “Cattle”
- Theresa Engel · Leidos Biomedical Research, Inc.$7,985,002
- Sonia Minikel Vallabh · Broad Institute, Inc.$4,896,596
- Subba Shankar · Collamedix Inc.$4,028,486
- Ramesha Papanna · University Of Texas Hlth Sci Ctr Houston$3,190,303
- Elizabeth Randall Nelson · Mother'S Milk Is Best, Inc.$3,118,212
- Ajay Houde · Annoviant, Inc$3,028,801
Research focus
CattleBlindnessLasersVascular Endothelial Growth FactorsOxygenExudative Age-Related Macular DegenerationIntravitreal InjectionIn VitroNeovascularizationVascular DiseasesRetinal DiseasesAnimal ModelCell ProliferationAge Related Macular DegenerationBevacizumabEndothelial CellsChoroidal NeovascularizationClinical TrialsCellsDesignHeparan Sulfate ProteoglycanHeparinAngiographyComplementary Dna
Grant awards (7)
Novel Long-Acting Inhibitors of Vascular Endothelial Growth Factor (VEGF) for Treatment of Intraocular Vascular Disorders$449,788
R01 · FY2024 · EY · contact PI
Novel Long-Acting Inhibitors of Vascular Endothelial Growth Factor (VEGF) for Treatment of Intraocular Vascular Disorders$449,788
R01 · FY2023 · EY · contact PI
Novel Long-Acting Inhibitors of Vascular Endothelial Growth Factor (VEGF) for Treatment of Intraocular Vascular Disorders$436,292
R01 · FY2022 · EY · contact PI
Novel Long-Acting Inhibitors of Vascular Endothelial Growth Factor (VEGF) for Treatment of Intraocular Vascular Disorders$481,890
R01 · FY2021 · EY · contact PI
Novel Long-Acting Inhibitors of Vascular Endothelial Growth Factor (VEGF) for Treatment of Intraocular Vascular Disorders$448,365
R01 · FY2020 · EY · contact PI
Identification of novel inhibitors of ocular neovascularization$196,719
R21 · FY2019 · EY · contact PI
Identification of novel inhibitors of ocular neovascularization$235,125
R21 · FY2018 · EY · contact PI